Hereditary non-polyposis colorectal cancer syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hereditary non-polyposis colorectal cancer syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Mesalamine to Prevent Colorectal Cancer in Patients with Lynch Syndrome https://clinicaltrials.eu/trial/study-on-mesalamine-to-prevent-colorectal-cancer-in-patients-with-lynch-syndrome/ Wed, 29 Apr 2026 15:02:15 +0000 https://clinicaltrials.eu/trial/study-on-mesalamine-to-prevent-colorectal-cancer-in-patients-with-lynch-syndrome/ This clinical trial is focused on studying Lynch syndrome, a genetic condition that increases the risk of developing colorectal cancer. The trial aims to test whether a medication called mesalamine (also known as 5-ASA) can help prevent the development of any colorectal tumors, both non-cancerous and cancerous, in patients with Lynch syndrome. Mesalamine is being compared to a placebo, which is a substance designed to look like the actual medication but does not contain any active ingredients.

Participants in the study will receive either mesalamine or the placebo over a period of 24 months, with an additional follow-up period of 3 months. During this time, regular colonoscopies, which are procedures that allow doctors to look inside the colon, will be conducted to monitor for any signs of tumor development. The goal is to see if mesalamine can reduce the occurrence of colorectal tumors compared to the placebo.

The study will also gather information on the number of tumors per patient, how the tumors progress, and whether the effects of the treatment vary based on factors like a patient’s history of colorectal cancer, gender, and age. Safety data will also be collected and compared between the groups receiving mesalamine and the placebo. This research is important for understanding how to better prevent colorectal cancer in individuals with Lynch syndrome.

]]> Study on the Effect of Low-Dose Aspirin in Preventing New or Recurrent Colorectal Polyps in Patients with Lynch Syndrome https://clinicaltrials.eu/trial/study-on-the-effect-of-low-dose-aspirin-in-preventing-new-or-recurrent-colorectal-polyps-in-patients-with-lynch-syndrome/ Wed, 29 Apr 2026 14:59:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-low-dose-aspirin-in-preventing-new-or-recurrent-colorectal-polyps-in-patients-with-lynch-syndrome/ This clinical trial is focused on studying the effects of a daily low-dose of aspirin on preventing new or returning growths in the colon, known as colorectal adenomas, in patients with Lynch syndrome. Lynch syndrome is a genetic condition that increases the risk of developing certain types of cancer, particularly in the colon. The study aims to explore whether taking aspirin daily can help reduce the occurrence of these growths compared to a placebo.

Participants in the study will be randomly assigned to receive either a low dose of aspirin (100 mg or 300 mg) or a placebo. The treatment will be administered in the form of a gastro-resistant tablet, which is designed to dissolve in the intestines rather than the stomach, to help minimize stomach irritation. The study will last for a period of 48 months, during which participants will undergo regular check-ups and procedures to monitor the development of any new colorectal adenomas.

The primary goal of the study is to determine the number of patients who develop at least one adenoma after 48 months of treatment. Secondary goals include measuring the time it takes for adenomas to appear after treatment begins, the number of adenomas based on specific genetic factors, and the overall burden of adenomatous polyps. The study will also track the occurrence of colon cancer and other related factors during the follow-up period. Participants will be monitored closely to ensure their safety and to assess the effectiveness of the aspirin treatment compared to the placebo.

]]>